GENFIT Achieves FDA Approval Milestone with Ipsen's Iqirvo® for Primary Biliary Cholangitis
Jun 11, 2024
Iqirvo Equities
Ipsen Achieves FDA Accelerated Approval for Iqirvo® as Innovative PPAR Treatment for Primary Biliary Cholangitis
Jun 11, 2024